This review summarizes the pharmacological properties of beta-blockers and affirms their clinical importance in managing angina pectoris and arrhythmias.
Reinforces beta-blockade centrality in angina and arrhythmias; extends foundational pharmacology but leaves open contemporary comparative trials.
The adrenergic ß‐receptor blocking drugs currently undergoing clinical evaluation are classified in relation to their pharmacological properties. Particular consideration is given to those pharmacological properties that may be of importance in the clinical application of these drugs. The present evidence on the role in the ß‐blocking action of propranolol in angina pectoris and arrhythmias is reviewed, and it is concluded that this property is of major significance in these indications. Finally, recent advances in this field are summarized and possible future areas for research described.
No takes yet. Share an insight, caveat, or question.
J.D. Fitzgerald (1969) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: